Transcenta Holding Limited (Transcenta), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilent Technologies, announce a collaboration to develop a Claudin18.2(CLDN18.2) companion diagnostic to support TranStar301 global phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line treatment in patients with CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal (G/GEJ) adenocarcinoma.
Agilent and UC San Diego Launch Center of Excellence in Cellular Intelligence
Agilent reports better-than-expected first quarter results, shares rise
Agilent Wins Two Scientists’ Choice Awards for Drug Discovery Products
Agilent Technologies announced the release of a new automated parallel capillary electrophoresis system for protein analysis – the Agilent ProteoAnalyzer system – at the 23rd Annual PepTalk Conference, being held January 16-19 in San Diego.
Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience
Agilent Names Philip Binns to Lead Life Sciences and Applied Markets Group
Not long after acquiring Resolution Bioscience in a deal worth more than half a billion dollars, Agilent Technologies has resolved to shutter the business, which was developing liquid biopsy tests that were powered by next-generation sequencing technology and meant to be used as companion diagnostics for cancer patients.
Aug 15 (Reuters) - Medical equipment maker Agilent Technologies (A.N) cut annual profit and sales forecasts for a second straight quarter as demand stays soft in major market China due to a slow economic recovery.